Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

ADP: 571K New Private-Sector Jobs, Better than Expected

571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.

Stock Market News for Nov 3, 2021

Wall Street maintained its northbound journey on Tuesday with all three major stock indexes closed at record-high levels for three consecutive days.

Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View

Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.

Nalak Das headshot

5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone

We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.

Fed Set to Start Vital FOMC Meeting

Fed Set to Start Vital FOMC Meeting.

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

Mark Vickery headshot

Fed Meets, Tapering in Our Midst; Pfizer Beats in Q3

The question now is: when will the Fed start tapering, and by how much?

Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 24.07% and 7.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Stock Market News for Nov 1, 2021

Wall Street closed higher on Friday despite weak earnings results of a couple of technology behemoths.

Nalak Das headshot

Top 6 Momentum Picks for November After a Fabulous October

We have narrowed down our search to six large-cap momentum stocks that have strong upside left for the rest of 2021. These are: BX, Ce, CLR, XLNX, BG, GPC.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Why Pfizer (PFE) Might Surprise This Earnings Season

Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View

Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $43.56, moving +0.95% from the previous trading session.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.